Bjoern Chapuy

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford et al. · Nature Medicine · 2018 · 2K citations · Full text

Medicine, Hematology, Oncology +12

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

Michael R. Green, Stefano Monti, Scott J. Rodig et al. · Blood · 2010 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +17

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand et al. · Journal of Clinical Oncology · 2016 · 1K citations · Full text

Medicine, Hematology, Oncology +17

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Jens G. Lohr, Petar Stojanov, Michael S. Lawrence et al. · Proceedings of the National Academy of Sciences · 2012 · 980 citations · Full text

Life Sciences, Genetics, Oncology +17